Advanced stage ovarian cancer patients with neoadjuvant chemotherapy suffered worse recurrence free survival

doi:10.21203/rs.2.20542/v1

PDF

Research

Advanced stage ovarian cancer patients with neoadjuvant chemotherapy suffered worse recurrence free survival

https://doi.org/10.21203/rs.2.20542/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted 09 Jan, 2020

You are reading this latest preprint version

Background

Neoadjuvant chemotherapy (NACT) has been applied for the treatment of patients with advanced-stage epithelial ovarian cancer (EOC), fallopian tube cancer, and primary peritoneal cancer, as these patients have a low likelihood of achieving optimal debulking and are thus poor surgical candidates. Herein, we explore the effects of NACT and compare the surgical outcomes and recurrence data in patients who receive interval debulking surgery followed NACT(NACT-IDS) or primary debulking surgery(PDS).

Methods

A retrospective, single-center, observational study was conducted. Patients with advanced-stage EOC, fallopian tube cancer and primary peritoneal cancer who were treated with NACT or primary debulking surgery were enrolled. The effects of NACT as well as the surgical outcomes and recurrence data were compared between the NACT-IDS and PDS groups.

Results

The albumin level was elevated (42.61±3.46 g/L vs. 37.47±5.42 g/L, P=0.001) and the levels of CA12-5 and HE4 significantly decreased (P=0.002, 0.003) in patients after neoadjuvant courses. The operation time, amount of blood loss during surgery, rate of bowel resection, time to chemotherapy, and platinum-free interval were comparable between the two groups (P＞0.05). Recurrence-free survival was worse in the NACT-IDS group than in the PDS group (HR=2.406, 95% CI[1.024, 5.657]).

Conclusion

NACT improved the condition of advanced-stage patients, but a poor recurrence free survival rate was observed; thus, NACT should not be applied in non-selected patients.

Cancer Biology

Sexual & Reproductive Medicine

Ovarian cancer

Adjuvant chemotherapy

Recurrence

Epithelial ovarian cancer (EOC) is the fifth most common type of cancer and the leading cause of death due to cancer in women; there were 295,414 newly diagnosed cases and 184,799 deaths in 2018 worldwide¹, and there were 22,530 cases and 13,980 deaths in 2019 in the United States². The standard management of ovarian cancer is a combination of cytoreductive surgery (primary debulking surgery) followed by platinum-based chemotherapy. The purpose of surgery is ideally to remove the tumor, with less than or equal to 1 cm of residual tumor, which is associated with a survival benefit³. However, more than 75% of OC patients diagnosed with advanced-stage disease have accompanying ascites and hypoalbuminemia, which are predictive of severe postoperative complications^4,5, and complications that occur after surgery delay adjuvant chemotherapy⁶. Therefore, neoadjuvant chemotherapy followed by interval debulking surgery is suggested⁷ for patients with advanced-stage disease who have a low likelihood of achieving optimal debulking and thus are poor surgical candidates. In addition, one study found higher quality of life scores in terms of emotional and cognitive function⁵. Importantly, the survival of patients who receive NACT followed by interval debulking surgery has been found to be no worse than the survival of those treated with PDS^8,9. Recently, the utilization of NACT has been proven to rapidly decrease 30- and 90-day mortality after surgery¹⁰.

In this study, we aimed to explore the effects of NACT and to compare the surgical outcomes and long-term recurrence information between an NACT-IDS and a PDS group.

Patient selection

Patients with epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer diagnosed by a pathologist and treated with NACT followed by interval debulking surgery (NACT-IDS) from January 1, 2013, to October 31, 2018, were considered potential participants. We also selected patients treated with primary debulking surgery (PDS) followed by platinum-based adjuvant chemotherapy during the same period for inclusion in the control group. The exclusion criteria were as follows: patients diagnosed with other malignant tumors and patients who did not undergo interval debulking surgery after NACT, or loss of follow-up. Informed consent was obtained.

We collected general information, including age, histology type, FIGO stage, and hemoglobin, albumin, alanine aminotransferase, aspartate aminotransferase, CA12-5, and HE4 levels before and after neoadjuvant therapy/surgery. We also collected information on the duration of surgery and the volume of bleeding during surgery as well as information regarding recurrence, platinum-free interval, and recurrence-free survival.

Follow-up

The follow-up period ended on December 31, 2019, and all included participants underwent regular tests for serum CA12-5 levels and abdominal/pelvic computerized tomography(CT)/ magnetic resonance imaging(MRI). Recurrence was defined as elevated serum CA12-5 levels (༞35 U/ml) as assessed by CT/MRI findings. The recurrence free survival was calculated from date of surgery to date of recurrence, and the platinum-free interval was calculated from the last chemotherapy cycle to the time of recurrence.

Statistical analysis

SPSS 19.0 was applied for the statistical analysis, and P༜0.05 was considered statistically significant. We used means ± standard deviations (SD) or medians (interquartile ranges) to express quantitative variables, and qualitative variables were expressed as absolute numbers (percentages). Student’s unpaired t test for variables with a normal distribution and the Mann-Whitney U test for variables with a nonnormal distribution were used for the comparison of quantitative variables between the groups, and the Chi-square test was used for qualitative variables. Kaplan-Meier survival analysis was used to analyze recurrence free survival with GraphPad Prism 8.0.

Clinical characteristics of the participators

Twenty-five patients received NACT followed by IDS, and 22 patients treated with PDS as the initial treatment were included. The baseline characteristics of the included patients are listed in Table 1. The age, FIGO stage, histology type, adjuvant chemotherapy cycle and rate of bowel resection were comparable between the NACT and PDS groups, while the diameters of the mass were larger in the PDS group than in the NACT group (P = 0.000).

Table 1

Characteristics of the participated patients
	NACT (n = 25)	PDS (n = 22)	P
Age (y)	58.96 ± 9.87	56.64 ± 10.64	0.442
FIGO stage (n, %)			0.578
Ⅱc	1	3
IIIc	22	16
IV	2	3
Histology type (n, %)			0.105
Serous	22	14
Other	3	8
Diameter (mm)	44.57 ± 25.74	85.94 ± 37.35	0.000
Neoadjuvant cycle	3 (2,3)	-	-
Adjuvant cycle	5.60 ± 2.33	5.43 ± 1.86	0.787
Bowel resection (n, %)	6, 24%	4, 18.18%	0.627
Length of follow-up, (Mean ± SD)	984.08 ± 543.62	758.41 ± 202.44	0.063

The effect of NACT

In the NACT group, serum markers were selected to evaluate the effect of NACT before and after the course of chemotherapy. Additionally, we found that the albumin level was elevated after chemotherapy (P = 0.001), while the CA12-5 and HE4 levels were obviously decreased posttreatment (P = 0.002, 0.003). In addition, the AST and ALT levels were comparable before and after the invention (P = 0.194, 0.074; Table 2).

Table 2

The serum biomarkers tested pre- and post-NACT
	Pre-NACT	Pos-NACT	P
Albumin, mean, SD (g/L)	37.47 ± 5.42	42.61 ± 3.46	0.001
Hemoglobin, mean, SD (g/L)	120.36 ± 15.91	105.61 ± 13.36	0.000
CA 12 − 5, mean, SD (U/ml)	1610.52 ± 1677.53	215.69 ± 316.39	0.002
HE4, median range (U/ml)	471.70 (77.12, 1527.24)	112.40 (38.81,1272.00)	0.003
ASL, mean, SD (U/L)	26.11 ± 13.78	30.58 ± 11.08	0.194
ALT, mean, SD (U/L)	19.30 ± 16.73	26.51 ± 12.35	0.074

The surgical outcomes and recurrence data of NACT-IDS and PDS

The preoperative hemoglobin and HE4 levels were lower in the NACT-IDS group than in the PDS group (P = 0.001, P = 0.031), and the AST and ALT levels were higher in the PDS group than in the NACT-IDS group (P = 0.005, P = 0.040); the operation time, blood loss during surgery, rate of bowel resection, and time from surgery to initial chemotherapy were comparable (P༞0.05). After the operation, the levels of hemoglobin and CA12-5 in the NAST-IDS group were lower than those in the PDS group (P = 0.022, P = 0.045). During the follow-up period, there were 14 patients with recurrence in the NACT group and 9 in the PDS group (P = 0.302). Among the patients who had recurrence, the platinum-free interval was 183.86 ± 89.28 days in the NACT-IDS group and 288.75 ± 188.56 days in the PDS group (P = 0.173). Additionally, there were 6/14 (42.86%) patients in the NACT-IDS group whose platinum-free interval was < 6 months and 2/9 (22.22%) patients in the PDS group (P = 0.333) (Table 3). Kaplan-Meier survival analysis for recurrence free survival demonstrated that patients who received NACT followed by IDS had a poor recurrence free survival (P = 0.0441). (Fig. 1)

Table 3

The surgical outcomes and recurrence data of NACT-IDS and PDS
	NACT (n = 25)	PDS (n = 22)	P
Operation time (min)	216.08 ± 61.23	240.82 ± 60.55	0.176
Blood loss (ml)	300.00(200.00,500.00)	300.00(200.00,600.00)	0.286
Bowel resection (n)	6(24.00%)	4(18.18%)	0.897
Time to chemotherapy (day)	11.00(9.00,18.50)	11.00(10.00,14.75)	0.792
Recurrence, n, %	14(56.00%)	8(36.36%)	0.178
Platinum-free interval (< 6 months), n, %	6(24.00%)	2(9.09%)	0.333
Platinum-free interval, day, mean ± SD	183.86 ± 89.28	288.75 ± 188.56	0.173

Ovarian cancer is the leading cause of death from gynecological malignancy worldwide, as most patients are diagnosed at advanced stages due to a lack of sensitive screening tests and the lack of specific symptoms at early stages. The standard of treatment is surgery followed by platinum-based chemotherapy¹¹, and optimal debulking is the goal, as residual tumors decrease progression-free survival and overall survival¹². To achieve the goal of optimal debulking, multivisceral surgeries such as bowel section and splenectomy are performed^13,14.

Invasive procedures are associated with high risks of morbidity and mortality; in addition, poor outcomes, such as hypoalbuminemia, are predictive of severe postoperative complications⁴, and complications delay the start of subsequent chemotherapy, which reduces progression-free survival⁶. Therefore, neoadjuvant chemotherapy offers an alternative treatment for patients with advanced ovarian cancer and makes surgery highly feasible¹⁵. In our study, we found that the level of albumin was elevated after the course of NACT (37.47 ± 5.42 vs 42.61 ± 3.46, P༜0.05). Cancer patients have low preoperative albumin levels, especially those with advanced-stage disease and patients with ascites¹⁶; the mechanisms for this low level involve a decrease in amino acid intake and albumin synthesis ¹⁷ as well as an increase in albumin leakage to the extravascular space in patients with ascites. There were 21 (80.77%) patients with massive ascites upon diagnosis, and the largest mean diameter of the ascites assessed by ultrasound was 104.05 ± 31.75 mm. After the course of NACT, ascites was not detected in 3 patients, and the largest mean diameter of the remaining cases of ascites was 65.00 ± 35.32 mm (t = 3.636, P = 0.001). Furthermore, decreases in CA12-5 and HE4 levels were found (P༜0.05) in the NACT group, and side effects of chemotherapy (lowered hemoglobin levels) also occurred. Previous studies have observed that patients who receive interval debulking surgery after NACT have better surgical outcomes than patients who receive PDS, including less severe surgical complexity, fewer upper abdominal procedures, a shorter surgical duration, a lower amount of perioperative blood loss, a shorter hospital stay^5,8,18, and reduced surgical morbidity and mortality^7,8. In our study, there was no difference in the surgical outcomes between the NACT and PDS groups, as NACT may induce fibrosis, which may influence surgical procedures.

The presence of residual disease after surgery largely impact the prognosis of EOC¹⁹; one study showed that the 7-year overall survival rate decreased from 73.6% in patients without residual tumors to 21% in patients with any type of residual disease²⁰. Therefore, the goal of debulking surgery has been changed from the presence of a residual tumor less than 1 cm in diameter to the presence of no visible tumor²¹; however, advanced-stage disease is associated with a low rate of complete tumor resection²². A previous study demonstrated that patients who received IDS after NACT were likely to achieve optimal cytoreduction^20,23 but that they did not have superior survival²⁴, and there was a decreasing trend in median survival with an increase in the number of NACT cycles^24,25. These studies suggest that NACT impacts the evaluation of tumor spread and leads to incomplete tumor resection in potentially resectable areas.

In addition, patients treated with NACT-IDS suffer from recurrence more often than patients treated with PDS²⁶. In our study, during the follow-up period, 14 (56.00%) patients experienced recurrence in the NACT group, and 8 (36.36%) had recurrence in the PDS group; the difference was not significant (P༞0.05). However, recurrence-free survival was poorer in the NACT-IDS group than in the PDS group (HR 2.406, 95% CI[1.024, 5.657]). Rauh-Hain and colleagues found that 88.8% of cases of recurrence in the NACT-IDS group were platinum resistant compared to 55.3% of cases in the PDS group (P = 0.001)²⁷. The same outcome was also found by Gao, who showed that 40.3% of patients in the NACT-IDS group and 23.1% in the PDS group experienced platinum-resistant recurrence and ²⁸; similarly, NACT induced chemotherapy resistance in cancer stem cell colonies²⁹. A limited number of studies have found that the TP53 gene mutation is the most common (70.3%) mutation after courses of NACT compared with before courses of NACT³⁰; additionally, in platinum-resistant patients (relapsed within 6 months), the TP53 K351N mutation was significantly more severe in the NACT-IDS group than in the PDS group (57.14% vs 0%, P༜0.01). Even so, in our study, we found that there was no significant difference in the platinum-free interval (164.93 ± 94.65 vs. 288.75 ± 188.56, P = 0.1115) or in the < 6-month PFI (6/25 vs. 2/22, P = 0.333).

There were some limitations in this study. First, this was a retrospective analysis in a single institution with a small sample size; thus, much stronger evidence is needed to confirm the results. Additionally, due to limited information, we did not compare overall survival between the two groups.

NACT improves the performance of patients, but patients suffered more recurrence during the follow-up period. NACT should not be applied in all advanced ovarian cancer patients without selected.

NACT: neoadjuvant chemotherapy; IDS: interval debulking surgery; PDS: primary debulking surgery; CT: computerized tomography; MRI: magnetic resonance imaging; SD: standard deviations; CI: confidence interval

Acknowledgements

None

Authors’ contributions

Cailiang Wu and Xuexin Zhou equally contribution to this manuscript, acquisition of data, analysis, and drafting the article. Yaping Zhu and Wei Bao contributed to the design of the study. Wei Xu, Yinyan He and Zhenyu Sang: interpretation of data. Cailiang Wu, Xuexin Zhou, Yi Miao, Long Zhou and Yiwen Feng: contribution to the concept of the study, coordinated the study. Cailiang Wu, Xuexin Zhou, Xing Li and Xiaoning Ji: contributed to the study execution and analysis.

Authors’ details

1 Department of gynaecology and obstetrics, Shanghai General Hospital, Shanghai 200080, China

Availability of data and materials

The data and materials used in the present study are available from the corresponding authors.( Also showed in Supplementary File)

Consent for publication

All of the authors read the final manuscript and consent for publication

Competing interests

None declared

Funding

The present study was sponsored by the National Natural Science Foundation of China (nos. 81972425), the Shanghai PuJiang Program (no. 17PJD032) and the Project Young Elite of the Shanghai Health System (no. 2017YQ063).

Ethics approval and consent to participate

Our study approved by the Ethics committee of Shanghai General Hospital, and all the informed consent of included patients obtained.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;6:394-424.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;1:7-34.
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;6:1234-1244.
Ataseven B, du Bois A, Reinthaller A, Traut A, Heitz F, Aust S, Prader S, et al. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol. 2015;3:560-565.
Fagotti A, Ferrandina G, Vizzielli G, Fanfani F, Gallotta V, Chiantera V, Costantini B, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016:22-33.
Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;1:15-20.
Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, Dizon DS, et al. Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;28:3460-3473.
Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;9990:249-257.
Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer. 2016:22-31.
Horner W, Peng K, Pleasant V, Brackmann M, Ebott J, Gutfreund R, McLean K, et al. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy. Gynecol Oncol. 2019;2:283-289.
Morotti M, Becker CM, Menada MV, Ferrero S. Targeting tyrosine-kinases in ovarian cancer. Expert Opin Investig Drugs. 2013;10:1265-1279.
Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;24:2489-2497.
Tozzi R, Hardern K, Gubbala K, Garruto Campanile R, Soleymani Majd H. En-bloc resection of the pelvis (EnBRP) in patients with stage IIIC-IV ovarian cancer: A 10 steps standardised technique. Surgical and survival outcomes of primary vs. interval surgery. Gynecol Oncol. 2017;3:564-570.
Soleymani Majd H, Ferrari F, Manek S, Gubbala K, Campanile RG, Hardern K, Tozzi R. Diaphragmatic peritonectomy vs. full thickness resection with pleurectomy during Visceral-Peritoneal Debulking (VPD) in 100 consecutive patients with stage IIIC-IV ovarian cancer: A surgical-histological analysis. Gynecol Oncol. 2016;3:430-435.
Worley MJ, Jr., Guseh SH, Rauh-Hain JA, Williams KA, Muto MG, Feltmate CM, Berkowitz RS, et al. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? Gynecol Oncol. 2013;1:69-73.
Ayhan A, Günakan E, Alyazıcı İ, Haberal N, Altundağ Ö, Dursun P. The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer. Arch Gynecol Obstet. 2017;5:989-995.
Ballmer PE, Ochsenbein AF, Schütz-Hofmann S. Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism. 1994;6:697-705.
Zhang H, Wang Y, Jiang Z-M, Kondrup J, Fang H, Andrews M, Nolan MT, et al. Impact of nutrition support on clinical outcome and cost-effectiveness analysis in patients at nutritional risk: A prospective cohort study with propensity score matching. Nutrition. 2017:53-59.
Winter WE, 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;24:3621-3627.
Rosen B, Laframboise S, Ferguson S, Dodge J, Bernardini M, Murphy J, Segev Y, et al. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer. Gynecol Oncol. 2014;3:462-467.
Chang S-J, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease. Gynecol Oncol. 2012;2:483-492.
Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, Woelber L, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data. Int J Gynecol Cancer. 2012;3:380-385.
Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, Mosgaard BJ, et al. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study. Gynecol Oncol. 2014;2:292-298.
Ren Y, Shi T, Jiang R, Yin S, Wang P, Zang R. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer. Int J Gynecol Cancer. 2015;8:1398-1404.
Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;3:1070-1076.
Himoto Y, Cybulska P, Shitano F, Sala E, Zheng J, Capanu M, Nougaret S, et al. Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? Gynecol Oncol. 2019;2:192-200.
Rauh-Hain JA, Nitschmann CC, Worley MJ, Jr., Bradford LS, Berkowitz RS, Schorge JO, Campos SM, et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013;1:63-68.
Gao Y, Li Y, Zhang C, Han J, Liang H, Zhang K, Guo H. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2019;1:85-85.
Lim MC, Song YJ, Seo S-S, Yoo C-W, Kang S, Park S-Y. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer. Onkologie. 2010;6:324-330.
Lee YJ, Kim D, Shim JE, Bae S-J, Jung Y-J, Kim S, Lee H, et al. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy. Int J Cancer. 2019:10.1002/ijc.32729.

nact.xlsx

PDF

Version 1

posted 09 Jan, 2020

You are reading this latest preprint version

Advanced stage ovarian cancer patients with neoadjuvant chemotherapy suffered worse recurrence free survival

Status:

Version 1

Abstract

Figures

Background

Methods

Patient selection

Follow-up

Statistical analysis

Results

Clinical characteristics of the participators

The effect of NACT

The surgical outcomes and recurrence data of NACT-IDS and PDS

Discussion

Conclusion

Abbreviations

Declarations

References

Supplementary Files

Status:

Version 1